TABLE 1.

Characteristics of LT recipients stratified according to the serologic response after 2 doses of the SARS‐CoV‐2 vaccines

Paper	Number of LT patients	Type of SARS‐CoV‐2 vaccine	Positive serological response rate	Antibody titre compared to the control group	Factors related to the reduced response rate
Guarino et al.	365	Pfizer‐ BioNTech BNT162b2	74.8%	214.79 ± 143 vs. 314.32 ± 94.1 AU/ml (p < .0001)	Age >65 years, higher BMI, shorter time from LT, immunos. Regimens with multiple drugs, antimetabolite T
Rabinowich et al.	80	Pfizer‐ BioNTech BNT162b2	47.5%	95.41 ± 92.4 vs. 200.5 ± 65.1) AU/ml (p < .001)	Age, lower eGFR, high dose predn. in the past 12, triple therapy immunos., MMF
Strauss et al.	161	Pfizer‐ BioNTech BNT162b2 Moderna mRNA‐1273	81%	81.9–250 U/ml, no control	Antimetabolite ther., type of vaccine
Rashidi‐Alavjeh et al.	43	Pfizer‐ BioNTech BNT162b2	79%	552.7 vs. >2080 BAU/ml (p = .0001)	MMF
Boyarsky et al.	129 (cohort of 658 SOT)	Pfizer‐ BioNTech BNT162b2 Moderna mRNA‐1273	79.8%		SOT: age, type of organ, years since TR, antimetabolite therapy, type of vaccine
Marion et al.	58 (cohort of 367 SOT)	Pfizer‐ BioNTech BNT162b2 Moderna mRNA‐1273	50%		No clinical data
Mazzola et al.	58 (cohort of 143 SOT)	Pfizer‐ BioNTech BNT162b2	37.5%		SOT: age >60, type of organ, treated with corticoids, triple‐ therapy immunosu., T <2 years, diabetic patients
Ruether et al.	141 (cohort of 194 pts, 53 cirr)	Pfizer‐ BioNTech BNT162b2 Moderna mRNA‐1273 Astra Zeneca	Anti‐S RBD 73.9% or the anti‐S Trimer 63.0%	163 (12–1060) 154 (1–1723)	Age > 65 years and arterial hypertension, vaccination failure was less likely with CNI monotherapy
Fernandez Ruiz et al.	14 (cohort of 44 patients, 28 kidney transplant, and 2 double organ)	Moderna mRNA‐1273	Anti‐S 57.1% N‐Ab activity 47.5%		MMF, Time from transplant >6 years, age >55 years
D’Offizi et al.	61	BNT162b2 or mRNA‐1273	Anti‐S 77% N‐Ab activity 57.5%